awmsg logo



rolapitant (Varuby®)


Reference No. 1303

Publication date:
05/03/2018


Appraisal information

rolapitant (Varuby®) 90 mg film-coated tablet


Company: TESARO UK Ltd
BNF category: Central nervous system
NMG meeting date: 10/01/2018
AWMSG meeting date: 14/02/2018
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0118
Ratification by Welsh Government: 05/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Rolapitant (Varuby) is not recommended for use within NHS Wales for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download